GVR Report cover Diabetes Associated Ophthalmic Treatment Market Size, Share & Trends Report

Diabetes Associated Ophthalmic Treatment Market Size, Share & Trends Analysis Report By Type (Drugs, Devices), By Application (Dry Eye, Glaucoma, Diabetic Retinopathy, DAMD, Uveitis, Cataract), By End-use, By Region, And Segment Forecasts, 2021 - 2028

  • Report ID: GVR-4-68039-553-5
  • Number of Report Pages: 178
  • Format: PDF, Horizon Databook
  • Historical Range: 2017 - 2019
  • Forecast Period: 2021 - 2028 
  • Industry: Healthcare

Report Overview 

The global diabetes associated ophthalmic treatment market size was valued at USD 27.2 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 6.5% from 2021 to 2028. The factors influencing the market growth include the increasing prevalence of type II diabetes, the growing geriatric population, rising incidences of vision loss due to excess diabetic condition, increasing awareness regarding ophthalmic disorders, and inclination towards early diagnosis. Furthermore, advancements in technology have resulted in the invention of new and safer products to treat diabetes associated ophthalmic diseases. However, the lack of skilled ophthalmologists and the longer duration of drug approvals are expected to hinder the market growth. 

Canada diabetes associated ophthalmic treatment market size, by type, 2018 - 2028 (USD Billion)

An increase in the incidence of diabetes due to aging, obesity, and an unhealthy lifestyle is one of the factors contributing to the growth of the market for diabetes-associated ophthalmic. Obesity is a major factor causing diabetes leading to the increased incidences of diabetes associated ophthalmic disorders. In 2017, the global incidence of diabetes was reported for around 22.9 million, the prevalence accounted for around 476.0 million, around 1.37 million deaths were reported due to diabetes, and disability-adjusted life-years (DALYs) associated with diabetes were reported to around 1.37 million. According to the WHO, in 2017, over 1.9 billion adults were overweight, of which, around 650 million people were classified as obese. Risk factors, such as obesity and overweight, are leading to an increase in the incidence of type II diabetes. Therefore, risk factors such as smoking, overweight, obesity, and high cholesterol are expected to boost the prevalence of type II diabetes.

Diabetes and ophthalmic conditions related to during and post-recovery of COVID-19 are expected to play an important market driver. Patients recovered from COVID-19 are showing long-term progressions in diabetic as well as ophthalmic conditions. Identification of new coronavirus strains is expected to increase the duration of the ongoing pandemic due to the limitation of the existing vaccines.

The increasing number of initiatives being undertaken by governments and nonprofit organizations to increase diabetes associated ophthalmic disease awareness is expected to boost the adoption of devices used for the treatment. Furthermore, WHO and IDF are working together to prevent and control diabetes and ensure good quality of life for people worldwide by providing accessible treatment facilities. For instance, WHO Diabetes Program is aimed at preventing type 2 diabetes, reducing complications, and improving quality of life. NGOs and governments are creating norms and standards, raising awareness about diabetes prevention, and promoting surveillance to strengthen the prevention and control of diabetes.

Type Insights

The drugs segment dominated the market for diabetes associated ophthalmic and accounted for the largest revenue share of 57.6% in 2020. The drug segment comprises anti-glaucoma drugs, anti-inflammatory drugs, anti-VEGF drugs, anti-allergy drugs, and others. The drug segment is propelling due to factors such as the presence of major key players operating in the global market, high adoption rate, increased clinical trials to develop innovative drugs. The devices segment is growing at a rapid pace accounted for a CAGR of 6.4% during the forecast period. The devices segment comprises refractive error surgical devices, glaucoma surgical devices, cataract surgical devices, vitreoretinal surgical devices, diagnostic devices, and visual aid devices.

End-use Insights

The hospital segment dominated the market for diabetes associated ophthalmic and accounted for the largest revenue share of 38.4% in 2020. An increasing number of hospital admissions of diabetes patients are boosting the demand for the segment, patients suffering from diabetes have a threefold chance of hospitalization compared with those without diabetes, thereby propelling the market growth.

Application Insights

The diabetic retinopathy segment dominated the market for diabetes associated ophthalmic and accounted for the largest revenue share of around 26.0% in 2020. Diabetic retinopathy is considered a critical medical condition that impacts the eyes of the patient leading to vision loss. According to the NCBI article (2014), around 1.5% of patients suffering from type II diabetes also have developed diabetic retinopathy, which leads to retinal neovascularization, hemorrhage, leakage of serum, and fibrovascular explosion in the vitreous retinal edge. 

Hence, if ignored, it may lead to severe blindness. Furthermore, increasing clinical trials for the approval of drugs used for the treatment of diabetic retinopathy is expected to boost the growth of the market for diabetes associated ophthalmic. For instance, North America accounted for the highest number of ongoing clinical trials i.e., 397, which is immediately followed by Europe accounting for 237 clinical trials.


Global diabetes associated ophthalmic treatment market share, by application, 2020 (%)

Regional Insights

North America dominated the diabetes associated ophthalmic treatment market and held the largest revenue share of 36.5% in 2020. The growth in the region is mainly attributed to factors such as robust healthcare infrastructure, rising patient awareness about early disease diagnosis and treatment, supportive reimbursement policies, and the increasing prevalence of diabetes. As per CDC, about 100 million American civilians have diabetes, which is considered one of the major causes of vision loss.  In addition, growing awareness regarding the availability of advanced options for treating diabetes associated ophthalmic conditions fuels the regional market growth. Furthermore, the presence of key players such as Pfizer, Inc., and Alcon in this region is expected to further boost the growth of the market for diabetes associated ophthalmic.

In Asia Pacific, the market for diabetes associated ophthalmic is expected to witness the fastest growth rate during the forecast period. The growing ophthalmic disorders burden and rising consumer awareness are expected to drive the market for diabetes associated ophthalmic in the region. Local companies are entering into strategic initiatives to develop and commercialize new treatment options for patients. This, in turn, is expected to boost the market growth.

Key Companies & Market Share Insights

Key players are involved in adopting strategies such as mergers and acquisitions, partnerships, and the launch of new technologically advanced products and services to strengthen their foothold in the market. Key players are significantly investing in research and development to manufacture technologically advanced products. For instance, in July 2021, F. Hoffmann-La Roche Ltd. announced that it has received USFDA’s acceptance for Biologics License Application (BLA), for faricimab that is used for the treatment of diabetic macular edema (DME) and macular degeneration, and diabetic retinopathy as well. Some of the prominent players in the diabetes associated ophthalmic treatment market include:

  • Alcon

  • Johnson & Johnson Services, Inc.

  • Bausch Health

  • F. Hoffmann-La Roche Ltd

  • Allergan

  • Bayer AG

  • Santen Pharmaceutical Co. Ltd.

  • Novartis AG

  • Pfizer, Inc.

  • Genentech, Inc.

  • Carl Zeiss Meditec

  • Lumenis

  • Ellex Medical Lasers Ltd.

  • IRIDEX Corp.

  • Topcon Corp.

  • Abbott Medical Optics

  • Quantel

Diabetes Associated Ophthalmic Treatment Market Report Scope

Report Attribute


Market size value in 2021

USD 28.7 billion

Revenue forecast in 2028

USD 44.7 billion

Growth Rate

CAGR of 6.5% from 2021 to 2028

Base year for estimation


Historical data

2017 - 2019

Forecast period

2021 - 2028

Quantitative units

Revenue in USD million and CAGR from 2021 to 2028

Report coverage

Revenue forecast, company ranking, competitive landscape, growth factors, and trends

Segments covered

Type, application; end-use; region

Regional scope

North America; Europe; Asia Pacific; Latin America; MEA

Country scope

U.S.; Canada; U.K.; Germany; France; Italy; Spain; Japan; India; China; Australia; South Korea; Brazil; Mexico; Argentina; Columbia; South Africa; Saudi Arabia; UAE

Key companies profiled

Alcon; Johnson & Johnson Services, Inc.; Bausch Health; Allergan; Bayer AG; Santen Pharmaceutical Co. Ltd.; Novartis AG; Pfizer, Inc.; Genentech, Inc.; Carl Zeiss Meditec; Lumenis; Ellex Medical Lasers Ltd.; IRIDEX Corporation; Topcon Corporation; Abbott Medical Optics; Quantel

Customization scope

Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.

Pricing and purchase options

Avail customized purchase options to meet your exact research needs. Explore purchase options


Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2028. For the purpose of this study, Grand View Research has segmented the global diabetes associated ophthalmic treatment market report on the basis of type, application, end-use, and region:

  • Application Outlook (Revenue, USD Million, 2017 - 2028)

    • Dry Eye Syndrome

    • Glaucoma

    • Eye Allergy & Infection

    • Diabetic Retinopathy

    • Diabetic associated Macular Degeneration

    • Uveitis

    • Cataract

    • Diabetic Macular Edema

    • Others

  • Type Outlook (Revenue, USD Million, 2017 - 2028)

    • Drugs

    • Devices

  • End-use Outlook (Revenue, USD Million, 2017 - 2028)

    • Hospitals

    • Ophthalmic Centers

    • Ambulatory Surgical Centers

    • Others

  • Regional Outlook (Revenue, USD Million, 2017 - 2028)

    • North America

      • U.S.

      • Canada

    • Europe

      • Germany

      • U.K.

      • France

      • Italy

      • Spain

    • Asia Pacific

      • China

      • Japan

      • India

      • Australia

      • South Korea

    • Latin America

      • Brazil

      • Mexico

      • Argentina

      • Colombia

    • Middle East & Africa

      • South Africa

      • Saudi Arabia

      • UAE

Frequently Asked Questions About This Report

gvr icn


gvr icn

This FREE sample includes data points, ranging from trend analyses to estimates and forecasts. See for yourself.

gvr icn


We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now

Certified Icon

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.